Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice

Journal of Inherited Metabolic Disease

Volumn 33, Issue 5, 2010, Pages 611-617

  Dunder, Ulla ^a,b   Valtonen, Pirjo ^b   Kelo, Eira ^b   Mononen, Ilkka ^c  

^a OK Kuopio   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID DERIVATIVE; ASPARTYLGLUCOSAMINE; N4 (BETA N ACETYLGLUCOSAMINYL)ASPARAGINASE; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTYLGLYCOSAMINURIA; BRAIN METABOLISM; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; EARLY INTERVENTION; ENZYME REPLACEMENT; MOUSE; NONHUMAN; TREATMENT DURATION;

ACETYLGLUCOSAMINE; AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ASPARTYLGLUCOSAMINURIA; ASPARTYLGLUCOSYLAMINASE; BIOLOGICAL MARKERS; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MICE; MICE, KNOCKOUT; NIH 3T3 CELLS; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFECTION;

EID: 77957586806     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9158-7     Document Type: Article

References (43)

1. Arvio M, Autio S, Mononen T (1997) Clinical manifestations of aspartylglycosaminuria. In: Mononen I, Aronson NN (eds) Lysosomal storage disease: aspartylglycosaminuria. R.G.Landes/Springer, Austin, pp 19-28
2. Aula P, Jalanko A, Peltonen L (2001) Aspartylglucosaminuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease I-VII. McGraw-Hill, New York, pp 3535-3550
3. NW Barton RO Brady JM Dambrosia, et al. 1991 Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease N Engl J Med 324 1464 1470 1:STN:280:DyaK3M3hvVyitg%3D%3D 10.1056/NEJM199105233242104 2023606
4. J Bielicki AC Crawley RC Davey JC Varnai JJ Hopwood 1999 Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI J Biol Chem 274 36335 36343 1:CAS:528: DC%2BD3cXitF2n 10.1074/jbc.274.51.36335 10593925 (Pubitemid 30005236)
5. AG Bijvoet HH Van MA Kroos, et al. 1999 Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II Hum Mol Genet 8 2145 2153 1:CAS:528:DyaK1MXnsVGns7Y%3D 10.1093/hmg/8.12.2145 10545593 (Pubitemid 29525328)
6. J Blanz S Stroobants R Lullmann-Rauch, et al. 2008 Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice Hum Mol Genet 17 3437 3445 1:CAS:528:DC%2BD1cXht12isb3N 10.1093/hmg/ddn237 18713755
7. G Bou-Gharios D Abraham I Olsen 1993 Lysosomal storage diseases: mechanisms of enzyme replacement therapy Histochem J 25 593 605 1:STN:280:DyaK2c%2Fkt1ahuw%3D%3D 10.1007/BF00157873 8226100
8. DA Brooks R Kakavanos JJ Hopwood 2003 Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder Trends Mol Med 9 450 453 1:CAS:528:DC%2BD3sXnvVKku7w%3D 10.1016/j.molmed.2003.08.004 14557058 (Pubitemid 37309647)
9. S Byers AC Crawley LK Brumfield JD Nuttall JJ Hopwood 2000 Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency Pediatr Res 47 743 749 1:CAS:528: DC%2BD3cXktlaisLs%3D 10.1203/00006450-200006000-00010 10832731
10. AC Crawley KH Niedzielski EL Isaac RC Davey S Byers JJ Hopwood 1997 Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI J Clin Invest 99 651 662 1:CAS:528:DyaK2sXhtlWjtrk%3D 10.1172/JCI119208 9045867 (Pubitemid 27097666)
11. RJ Desnick R Brady J Barranger, et al. 2003 Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy Ann Intern Med 138 338 346 12585833
12. U Dunder V Kaartinen P Valtonen, et al. 2000 Enzyme replacement therapy in a mouse model of aspartylglycosaminuria FASEB J 14 361 367 1:CAS:528:DC%2BD3cXisFKksr8%3D 10657992
13. GA Grabowski NW Barton G Pastores, et al. 1995 Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources Ann Intern Med 122 33 39 1:STN:280:DyaK2M%2FnslaisA%3D%3D 7985893
14. JH Grubb C Vogler B Levy N Galvin Y Tan WS Sly 2008 Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII Proc Natl Acad Sci USA 105 2616 2621 1:CAS:528:DC%2BD1cXis1Oqtb8%3D 10.1073/pnas.0712147105 18268347 (Pubitemid 351520562)
15. P Harmatz R Giugliani IV Schwartz, et al. 2008 Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase Mol Genet Metab 94 469 475 1:CAS:528:DC%2BD1cXosVOnurs%3D 10.1016/j.ymgme.2008.04.001 18502162
16. V Kaartinen I Mononen 1990 Detection of aspartylglycosaminuria using urine specimens recovered from absorbent filter paper Clin Chim Acta 191 15 20 1:CAS:528:DyaK3MXitVeluw%3D%3D 10.1016/0009-8981(90)90053-U 2073730
17. V Kaartinen I Mononen 1990 Assay of aspartylglycosylaminase by high-performance liquid chromatography Anal Biochem 190 98 101 1:CAS:528:DyaK3MXlslyntg%3D%3D 10.1016/0003-2697(90)90140-5 2285152
18. V Kaartinen JC Williams J Tomich JR Yates III LE Hood I Mononen 1991 Glycosaparaginase from human leukocytes. Inactivation and covalent modification with diazo-oxonorvaline J Biol Chem 266 5860 5869 1:CAS:528:DyaK3MXisVegtLw%3D 2005122
19. V Kaartinen I Mononen JW Voncken T Noronkoski I Gonzalez-Gomez N Heisterkamp J Groffen 1996 A mouse model for the human lysosomal disease aspartylglycosaminuria Nat Med 2 1375 1378 1:CAS:528:DyaK28Xntlyrsro%3D 10.1038/nm1296-1375 8946839 (Pubitemid 26401743)
20. R Kakavanos CT Turner JJ Hopwood ED Kakkis DA Brooks 2003 Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I Lancet 361 1608 1613 1:CAS:528:DC%2BD3sXjs1Wltbc%3D 10.1016/S0140-6736(03)13311-9 12747881 (Pubitemid 36578998)
21. ED Kakkis MF McEntee A Schmidtchen, et al. 1996 Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I Biochem Mol Med 58 156 167 1:CAS:528:DyaK28XltVKqsLo%3D 10.1006/bmme.1996.0044 8812735 (Pubitemid 26262358)
22. LW Katzin AA Amato 2008 Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy J Clin Neuromuscul Dis 9 421 431 10.1097/CND.0b013e318176dbe4 18525427
23. E Kelo U Dunder I Mononen 2005 Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy Glycobiology 15 79 85 1:CAS:528:DC%2BD2cXhtVKqu7nL 10.1093/glycob/cwh145 15342551 (Pubitemid 40202041)
24. O Lidove D Joly F Barbey, et al. 2007 Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature Int J Clin Pract 61 293 302 1:CAS:528:DC%2BD2sXjs1Wks78%3D 10.1111/j.1742-1241.2006. 01237.x 17263716
25. U Matzner E Herbst KK Hedayati, et al. 2005 Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy Hum Mol Genet 14 1139 1152 1:CAS:528:DC%2BD2MXjvFamur8%3D 10.1093/hmg/ddi126 15772092 (Pubitemid 40613903)
26. U Matzner R Lullmann-Rauch S Stroobants, et al. 2009 Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy Mol Ther 17 600 606 1:CAS:528: DC%2BD1MXhtVent7w%3D 10.1038/mt.2008.305 19174759
27. Mononen I, Aronson NN Jr (1997) Lysosomal storage disease: aspartylglycosaminuria. R.G.Landes/Springer, Austin
28. IT Mononen VM Kaartinen JC Williams 1993 A fluorometric assay for glycosylasparaginase activity and detection of aspartylglycosaminuria Anal Biochem 208 372 374 1:CAS:528:DyaK3sXhvVKnsr0%3D 10.1006/abio.1993.1063 8452235 (Pubitemid 23084688)
29. I Mononen N Heisterkamp U Dunder EL Romppanen T Noronkoski I Kuronen J Groffen 1995 Recombinant glycosylasparaginase and in vitro correction of aspartylglycosaminuria FASEB J 9 428 433 1:CAS:528:DyaK2MXks12nt7Y%3D 7896015
30. C Porto M Cardone F Fontana, et al. 2009 The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts Mol Ther 17 964 971 1:CAS:528:DC%2BD1MXjt1Gnsbs%3D 10.1038/mt.2009.53 19293774
31. DP Roces R Lullmann-Rauch, et al. 2004 Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study Hum Mol Genet 13 1979 1988 1:CAS:528:DC%2BD2cXnsVyis74%3D 10.1093/hmg/ddh220 15269179 (Pubitemid 39377822)
32. RM Shull ED Kakkis MF McEntee SA Kania AJ Jonas EF Neufeld 1994 Enzyme replacement in a canine model of Hurler syndrome Proc Natl Acad Sci USA 91 12937 12941 1:CAS:528:DyaK2MXivVCqsLg%3D 10.1073/pnas.91.26.12937 7809150
33. M Sifuentes R Doroshow R Hoft, et al. 2007 A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years Mol Genet Metab 90 171 180 1:CAS:528:DC%2BD2sXnsl2kuw%3D%3D 10.1016/j.ymgme.2006.08. 007 17011223 (Pubitemid 46108607)
34. WS Sly 2000 The missing link in lysosomal enzyme targeting J Clin Invest 105 563 564 1:CAS:528:DC%2BD3cXhslygsLY%3D 10.1172/JCI9479 10712426
35. K Stewart OA Brown AE Morelli, et al. 1997 Uptake of alpha-(L)- iduronidase produced by retrovirally transduced fibroblasts into neuronal and glial cells in vitro Gene Ther 4 63 75 1:CAS:528:DyaK2sXot1Wrtw%3D%3D 10.1038/sj.gt.3300364 9068797
36. CT Turner JJ Hopwood DA Brooks 2000 Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats Mol Genet Metab 69 277 285 1:CAS:528:DC%2BD3cXkt1ensbs%3D 10.1006/mgme.2000.2979 10870845 (Pubitemid 30333662)
37. A Urayama JH Grubb WS Sly WA Banks 2004 Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier Proc Natl Acad Sci USA 101 12658 12663 1:CAS:528: DC%2BD2cXnsVentrc%3D 10.1073/pnas.0405042101 15314220 (Pubitemid 39122079)
38. A Urayama JH Grubb WS Sly WA Banks 2008 Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse Mol Ther 16 1261 1266 1:CAS:528:DC%2BD1cXns1eiu7Y%3D 10.1038/mt.2008.84 18443601 (Pubitemid 351866057)
39. C Vogler MS Sands B Levy N Galvin EH Birkenmeier WS Sly 1996 Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival Pediatr Res 39 1050 1054 1:CAS:528:DyaK28XktlyrsbY%3D 10.1203/00006450-199606000-00019 8725268
40. C Vogler B Levy JH Grubb, et al. 2005 Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII Proc Natl Acad Sci USA 102 14777 14782 1:CAS:528:DC%2BD2MXhtFKjsbzN 10.1073/pnas.0506892102 16162667 (Pubitemid 41457132)
41. D Wang EJ Bonten G Yogalingam L Mann A d'Azzo 2005 Short-term, high dose enzyme replacement therapy in sialidosis mice Mol Genet Metab 85 181 189 1:CAS:528:DC%2BD2MXlsFGgsrs%3D 10.1016/j.ymgme.2005.03.007 15979029 (Pubitemid 40840757)
42. JE Wraith 2008 Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II Acta Paediatr Suppl 97 76 78 10.1111/j.1651-2227.2008.00661.x 18339193 (Pubitemid 351421301)
43. JE Wraith LA Clarke M Beck, et al. 2004 Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) J Pediatr 144 581 588 1:CAS:528:DC%2BD2cXjs1Wnsbg%3D 10.1016/j.jpeds.2004.01.046 15126990 (Pubitemid 38594757)